

Intra-Cellular Therapies, Inc.
 Form 3
 September 09, 2013

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| | | | | | |
|--|--|--|--|--|---|
| 1. Name and Address of Reporting Person * Â Fienberg Allen A. (Last) (First) (Middle) C/O INTRA-CELLULAR THERAPIES, INC., Â 3960 BROADWAY (Street) NEW YORK, Â NY Â 10032 (City) (State) (Zip) | 2. Date of Event Requiring Statement (Month/Day/Year) 08/29/2013 | 3. Issuer Name and Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [NONE] | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) VP of Business Development | 5. If Amendment, Date Original Filed(Month/Day/Year) | 6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person |
|--|--|--|--|--|---|

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|------------------------------------|--|---|--|
| Common Stock | 237,500 | D | Â |
| Common Stock | 208,023 | I | Held by J.D.F. Holdings Ltd. ⁽¹⁾ |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security | 4. Conversion or Exercise | 5. Ownership Form of | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---|---|--|---------------------------|----------------------|--|
|---|---|--|---------------------------|----------------------|--|

Edgar Filing: Intra-Cellular Therapies, Inc. - Form 3

| | Date Exercisable | Expiration Date | (Instr. 4) Title | Amount or Number of Shares | Price of Derivative Security | Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | |
|-----------------------------|------------------|-----------------|---------------------|----------------------------|------------------------------|--|---|
| Stock Option (right to buy) | Â (2) | 12/19/2014 | Common Stock | 37,500 | \$ 0.5 | D | Â |
| Stock Option (right to buy) | Â (2) | 12/14/2015 | Common Stock | 12,500 | \$ 0.6 | D | Â |
| Stock Option (right to buy) | Â (2) | 12/05/2016 | Common Stock | 12,500 | \$ 1.36 | D | Â |
| Stock Option (right to buy) | Â (2) | 12/12/2017 | Common Stock | 12,500 | \$ 1.5 | D | Â |
| Stock Option (right to buy) | Â (2) | 12/18/2018 | Common Stock | 10,000 | \$ 1.5 | D | Â |
| Stock Option (right to buy) | Â (2) | 06/10/2020 | Common Stock | 10,000 | \$ 2.74 | D | Â |
| Stock Option (right to buy) | Â (3) | 12/21/2020 | Common Stock | 10,000 | \$ 2.74 | D | Â |
| Stock Option (right to buy) | Â (4) | 04/30/2022 | Common Stock | 10,000 | \$ 2.84 | D | Â |
| Stock Option (right to buy) | Â (5) | 05/30/2023 | Common Stock | 7,500 | \$ 3.26 | D | Â |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|------------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Fienberg Allen A. C/O INTRA-CELLULAR THERAPIES, INC. 3960 BROADWAY NEW YORK, NY 10032 | Â | Â | Â VP of Business Development | Â |

Signatures

/s/ Larry J. Himeline,
Attorney-in-fact

09/09/2013

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Dr. Fienberg holds a 20% ownership interest in J.D.F. Holdings Ltd. and may be deemed to beneficially own the securities held by J.D.F. Holdings Ltd. Dr. Fienberg disclaims beneficial ownership of the securities held by J.D.F. Holdings Ltd. except to the extent of his pecuniary interest therein.

Edgar Filing: Intra-Cellular Therapies, Inc. - Form 3

- (2) All shares underlying this option have vested.
- (3) The option vests as to one third of the shares on December 22, 2011, one third of the shares on December 22, 2012 and one third of the shares on December 22, 2013.
- (4) The option vests as to one third of the shares on December 20, 2012, one third of the shares on December 20, 2013 and one third of the shares on December 20, 2014.
- (5) The option vests as to one third of the shares on December 20, 2013, one third of the shares on December 20, 2014 and one third of the shares on December 20, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.